BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets
TheFly reported on January 20 that BofA raised its price target on NVAX to $7 from $6 while maintaining an Underperform rating.
Novavax Inc (NVAX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Shah Capital Management Himanshu H. Shah | 14,558,780 | $97,835,002 | +24% | 18.87% |
| 2. | D E Shaw D. E. Shaw | 5,992,798 | $40,271,603 | +41% | 0.02% |
| 3. | Millennium Management Israel Englander | 4,470,083 | $30,038,958 | +111% | 0.01% |
| 4. | 2,530,600 | $17,005,632 | -1% | 0.41% | |
| 5. | 12,000,000 | $12,854,880 | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.50 | 1,000 | $6,500.00 | 14,473 | 2023-03-10 | Filing | |
| $7.04 | 2,000 | $14,088.00 | 13,473 | 2023-03-07 | Filing | |
| $7.48 | 3,000 | $22,453.50 | 11,473 | 2023-03-06 | Filing | |
| $139.64 | 700 | $97,748.00 | 2,800 | 2021-05-19 | Filing | |
| $48.83 | 1,500 | $73,245.00 | 1,500 | 2020-06-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.02 | 4,150 | $37,435.08 | 14,770 | 2024-12-13 | Filing | |
| $8.00 | 5,400 | $43,200.00 | 51,760 | 2024-12-31 | Filing | |
| $8.48 | 4,600 | $39,008.00 | 57,160 | 2024-12-24 | Filing | |
| $14.09 | 7,500 | $105,675.00 | 61,760 | 2024-06-21 | Filing | |
| $14.28 | 1,107 | $15,807.96 | 69,260 | 2024-06-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,470,365 | $103,960,853 | 0% | |
| 2. | 12,901,549 | $86,698,409 | 0% | |
| 3. | 9,523,646 | $63,998,901 | 0% | |
| 4. | 8,290,665 | $55,713,268 | 0% | |
| 5. | 6,880,481 | $46,236,832 | 14.9% |
News See All
9 High Growth Small Cap Stocks That Are Profitable
As strategists weigh solid earnings momentum against expensive valuations and longer-term dangers, market opinions are still divided.
Novavax, Inc. (NVAX): A Bull Case Theory
We came across a bullish thesis on Novavax, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on NVAX.
Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast
Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc.
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.
Novavax, Inc. (NASDAQ:NVAX) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Novavax's Third Quarter 2025 Financial Results and Operational Highlights Conference Call.
Novavax (NVAX) Gains Momentum with Sanofi Deal and Analyst Endorsement
Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald initiated coverage of Novavax, Inc.
Top 8 Long-Term Biotechnology Stocks to Buy
Momentum in biotechnology stocks is accelerating after years of underperformance.
Hedge Fund Resource Center Billionaire Hedge Funds
